← Back to patent-cliff list
CAS 57260-71-6
tert-butyl piperazine-1-carboxylateN-Boc 哌嗪哌嗪-1-甲酸叔丁酯1-Boc-piperazineN-BOC-piperazine
Codes：PALB-012、OLAP-007、VENE-015、AVAPR-002、BREX-008、CARI-002、VORT-017
Physicochemical properties & identification
- Formula
- C9H18N2O2
- Mol. weight
- 186.26
- Appearance
- 白色至类白色结晶粉末
- Melting point
- 约 49 – 53 °C
- Solubility
- 溶于乙醇、乙酸乙酯、DCM；微溶于水
- Storage
- 密封干燥；常规 Boc 保护胺操作防护
Applications
- · 单边保护哌嗪的标准砌块：CNS 药物（卡利拉嗪等）与众多含哌嗪 API 的选择性 N-烷基化策略
- · 偶联/linker 化学与高通量合成的常用中间体
Application context (from source-drug indications)
乳腺癌哌柏西利子宫内膜癌奥拉帕利去势抵抗性前列腺肿瘤奥拉帕利前列腺癌奥拉帕利腹膜癌奥拉帕利卵巢上皮癌奥拉帕利输卵管癌奥拉帕利急性髓细胞样白血病维奈克拉慢性淋巴细胞白血病维奈克拉系统性肥大细胞增多症阿伐替尼胃肠道间质瘤阿伐替尼肥大细胞白血病阿伐替尼精神分裂症布瑞哌唑阿尔茨海默病布瑞哌唑躁动布瑞哌唑抑郁布瑞哌唑抑郁症布瑞哌唑重度抑郁症布瑞哌唑重度抑郁症卡利拉嗪盐酸盐精神分裂症卡利拉嗪盐酸盐躁狂症卡利拉嗪盐酸盐重度抑郁症氢溴酸伏硫西汀术后疼痛氢溴酸伏硫西汀大麻依赖氢溴酸伏硫西汀焦虑氢溴酸伏硫西汀焦虑症氢溴酸伏硫西汀抑郁氢溴酸伏硫西汀
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 哌柏西利Palbociclib | Tier A — Act now | 2027 |
| 奥拉帕利Olaparib | Tier A — Act now | 2028 |
| 维奈克拉Venetoclax | Tier B — Position early | 2030 |
| 阿伐替尼Avapritinib | Tier C — Watch / trade | 2032 |
| 布瑞哌唑Brexpiprazole | Tier A — Act now | 2029 |
| 卡利拉嗪盐酸盐Cariprazine Hydrochloride | Tier A — Act now | 2029 |
| 氢溴酸伏硫西汀Vortioxetine Hydrobromide | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
tert-butyl piperazine-1-carboxylate→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate→5-bromo-2,4-dichloropyrimidine→cyclopentanamine→5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine→(E)-but-2-enoic acid→2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one→6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one→tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→tert-butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→1-(vinyloxy)butane→tert-butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→5-bromo-2-nitropyridine
3-hydroxyisobenzofuran-1(3H)-one→dimethyl phosphonate→dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate→2-fluoro-5-formylbenzonitrile→(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate→4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one→cyclopropanecarbonyl chloride
5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-5-ol→methyl 2,4-difluorobenzoate→methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoate→1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine→methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate→5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→methyl 4,4-dimethyl-2-oxocyclohexane-1-carboxylate→methyl 4,4-dimethyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-ene-1-carboxylate→(4-chlorophenyl)boronic acid→methyl 4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carboxylate→(4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol→tert-butyl piperazine-1-carboxylate→tert-butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate
5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→(4-chlorophenyl)boronic acid→tert-butyl piperazine-1-carboxylate→tert-butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate→4-bromo-2-fluoro-1-iodobenzene→VENE-018→1H-pyrrolo[2,3-b]pyridin-5-ol→tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate→1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine→4-(di-tert-butylphosphanyl)-N,N-dimethylaniline→tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate→3,3-dimethylcyclohexanone→2-chloro-4,4-dimethylcyclohex-1-ene-1-carbaldehyde→4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde
1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→6-bromopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→ethyl 2-chloropyrimidine-5-carboxylate→tert-butyl piperazine-1-carboxylate→ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate→2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid→N,O-dimethylhydroxylamine→tert-butyl 4-(5-(methoxy(methyl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)magnesium bromide→tert-butyl 4-(5-(4-fluorobenzoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)(2-(piperazin-1-yl)pyrimidin-5-yl)methanone hydrochloride→4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine→(4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methanone→(S)-2-methylpropane-2-sulfinamide→(Z)-N-((4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methylene)-2-methylpropane-2-sulfinamide→N-(1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethyl)-2-methylpropane-2-sulfinamide
2-chloro-6-fluorobenzaldehyde→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(3-chloro-2-formylphenyl)piperazine-1-carboxylate→ethyl 2-mercaptoacetate→tert-butyl 4-(2-(ethoxycarbonyl)benzo[b]thiophen-4-yl)piperazine-1-carboxylate→4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzo[b]thiophene-2-carboxylic acid→tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-1-carboxylate
1-bromo-2,3-dichlorobenzene→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2,3-dichlorophenyl)piperazine-1-carboxylate→1-(2,3-dichlorophenyl)piperazine hydrochloride→tert-butyl ((1r,4r)-4-(2-oxoethyl)cyclohexyl)carbamate→tert-butyl ((1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)carbamate→(1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexanamine→dimethylcarbamic chloride
1-((2-fluorophenyl)sulfinyl)-2,4-dimethylbenzene→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2-((2,4-dimethylphenyl)sulfinyl)phenyl)piperazine-1-carboxylate→1-(2-((2,4-dimethylphenyl)sulfinyl)phenyl)piperazine→2,4-dimethylbenzenethiol→1,2-difluorobenzene→(2,4-dimethylphenyl)(2-fluorophenyl)sulfane
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | Ethyl 2-chloropyrimidine-5-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 1-Methyl-4-pyrazole boronic acid pinacol ester Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-Fluoro-5-formylbenzonitrile Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 1-(Cyclopropylcarbonyl)piperazine hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | PD 0332991 HCl Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.